USMLE Step 1 & 2 Viruses and Antivirals
Last updated: May 2, 2026
Viruses and Antivirals questions are one of the highest-leverage areas to study for the USMLE Step 1 & 2. This guide breaks down the rule, the elements you need to recognize, the named traps that catch most students, and a memory aid that scales to test day. Read it once, then practice the same sub-topic adaptively in the app.
The rule
Antiviral drugs target distinct steps in the viral life cycle: attachment/entry, uncoating, genome replication (DNA polymerase, reverse transcriptase, RNA polymerase), integration, protein processing (protease), and release (neuraminidase). To pick the right drug or predict a resistance mechanism on the exam, first identify the virus family and its replication strategy, then match the drug class to the step it blocks. Resistance almost always traces back to a mutation in the viral target (thymidine kinase, reverse transcriptase, neuraminidase, NS5A) or to a missing activating enzyme.
Elements breakdown
Herpesvirus antivirals
Drugs targeting HSV-1/2, VZV, CMV, EBV, HHV-6/8 — all dsDNA viruses replicating in the nucleus
- Acyclovir/valacyclovir: activated by viral thymidine kinase
- Famciclovir/penciclovir: similar TK-dependent activation
- Ganciclovir/valganciclovir: CMV, activated by UL97 kinase
- Foscarnet: pyrophosphate analog, no kinase needed
- Cidofovir: nucleotide analog, no kinase needed
- Letermovir: CMV terminase complex inhibitor
Common examples:
- Acyclovir-resistant HSV in AIDS patient → use foscarnet
HIV antiretrovirals
Drugs targeting reverse transcriptase, integrase, protease, and entry of HIV-1
- NRTIs: chain terminators (tenofovir, emtricitabine, abacavir, zidovudine)
- NNRTIs: allosteric RT inhibitors (efavirenz, rilpivirine, doravirine)
- Integrase strand transfer inhibitors: dolutegravir, bictegravir, raltegravir
- Protease inhibitors: -navir suffix (darunavir, atazanavir)
- Entry inhibitors: maraviroc (CCR5), enfuvirtide (gp41)
Common examples:
- Standard initial therapy: 2 NRTIs + INSTI (e.g., bictegravir/tenofovir/emtricitabine)
Influenza antivirals
Drugs targeting influenza A and B replication and release
- Oseltamivir/zanamivir: neuraminidase inhibitors
- Baloxavir: cap-dependent endonuclease inhibitor (PA subunit)
- Amantadine/rimantadine: M2 channel blockers — now obsolete due to resistance
- Best benefit when started <48 hours from symptom onset
Common examples:
- Outpatient with 24-hour fever, cough, myalgias and positive flu A swab → oseltamivir
Hepatitis antivirals
Drugs targeting HBV (dsDNA, reverse-transcribing) and HCV (ssRNA+) replication
- HBV: tenofovir, entecavir — chronic suppression, rarely cure
- HCV direct-acting antivirals: NS3/4A protease (-previr), NS5A (-asvir), NS5B polymerase (-buvir)
- Common HCV regimen: sofosbuvir/velpatasvir — pangenotypic
- Hepatitis A and E: no specific antiviral, supportive only
Common examples:
- Treatment-naive HCV genotype 1 → 12 weeks sofosbuvir/velpatasvir
Other clinically important antivirals
Drugs for RSV, CMV, and emerging viruses tested on Step 2 CK
- Ribavirin: RSV (rare), HCV adjunct historically, Lassa
- Palivizumab: monoclonal anti-RSV F protein for high-risk infants
- Remdesivir: RNA polymerase inhibitor, SARS-CoV-2 and Ebola
- Nirmatrelvir/ritonavir: SARS-CoV-2 main protease (Mpro) inhibitor
Common examples:
- Premature infant with chronic lung disease → monthly palivizumab in RSV season
Common patterns and traps
The Activation-Dependence Trap
Many antivirals are prodrugs that require a viral enzyme (HSV/VZV thymidine kinase, CMV UL97 kinase) to perform the first phosphorylation. When the stem describes a resistant strain, the most common mechanism is loss of that activating kinase, not a polymerase mutation. The correct rescue drug is one that does not need kinase activation — typically foscarnet or cidofovir.
A bone-marrow-transplant patient with persistent HSV ulcers despite acyclovir; the right answer is foscarnet, the trap is increasing the acyclovir dose.
The Drug-Suffix Decoder
USMLE leans heavily on suffix patterns for HIV and HCV drugs. -navir is a protease inhibitor, -tegravir is an integrase inhibitor, -previr is HCV NS3/4A protease, -asvir is HCV NS5A, -buvir is HCV NS5B polymerase. Recognizing the suffix lets you assign mechanism even for unfamiliar drug names.
A question naming 'glecaprevir/pibrentasvir' and asking the mechanism — answer combines NS3/4A protease inhibition and NS5A inhibition.
The Wrong-Virus Distractor
Distractors offer drugs that work for a related but different virus: ganciclovir for an HSV question, acyclovir for a CMV question, oseltamivir for an RSV question. The trap rewards memorizing 'antiviral' as a single category instead of mapping each drug to its specific virus.
Choices include acyclovir, ganciclovir, foscarnet, and cidofovir for a stem that is actually about CMV — acyclovir is the seductive but wrong answer.
The 48-Hour Window
Influenza neuraminidase inhibitors and baloxavir give meaningful clinical benefit only when started within 48 hours of symptom onset in otherwise healthy outpatients. Stems will dangle a 4-day or 5-day symptom duration to test whether you withhold the drug or still treat in hospitalized/high-risk patients (where you treat regardless of duration).
Healthy adult presenting day 4 with flu symptoms — best answer is supportive care, not oseltamivir.
The Mechanism-Substitution Trap
A wrong choice describes a real antiviral mechanism but for a drug that does not exist or is used in a different virus family. For example, 'inhibits viral neuraminidase' offered for a herpes question, or 'inhibits reverse transcriptase' offered for an influenza question. The trap exploits candidates who match keywords without checking the virus.
A CMV question lists 'inhibits viral neuraminidase' as a distractor — sounds antiviral, wrong family.
How it works
Imagine Mr. Patel, a 58-year-old kidney transplant recipient, develops blurry vision and is found to have CMV retinitis with viremia. Knowing CMV is a herpesvirus that uses its UL97 kinase to phosphorylate ganciclovir, you select valganciclovir as first-line therapy. Two weeks later, his viral load rises despite adherence, and genotyping reveals a UL97 mutation. The exam wants you to recognize that resistance has eliminated the activating step, so you pivot to foscarnet, which directly inhibits the viral DNA polymerase without needing kinase activation. The same reasoning chain — identify the virus, identify the drug's target, identify the resistance mechanism — solves nearly every antiviral question on Step 1 and Step 2 CK. When the stem mentions a specific viral protein mutation, ask which drug depends on that protein; that drug fails, and the alternative that bypasses the mutated protein wins.
Worked examples
Which of the following is the most appropriate next step in antiviral therapy?
- A Increase acyclovir to high-dose intravenous therapy
- B Switch to intravenous foscarnet ✓ Correct
- C Switch to oral valganciclovir
- D Switch to oral oseltamivir
Why B is correct: UL23 encodes HSV thymidine kinase, the enzyme that performs the first phosphorylation of acyclovir to its monophosphate form. A frameshift mutation eliminates kinase activity, so any acyclovir-class drug — regardless of dose or route — cannot be activated. Foscarnet is a pyrophosphate analog that directly inhibits viral DNA polymerase without requiring kinase activation, making it the drug of choice for TK-deficient acyclovir-resistant HSV.
Why each wrong choice fails:
- A: The defect is loss of the activating enzyme, not insufficient drug exposure; no amount of acyclovir can be phosphorylated to its active form when thymidine kinase is absent. (The Activation-Dependence Trap)
- C: Valganciclovir also requires phosphorylation, primarily by CMV UL97 kinase; while HSV can phosphorylate ganciclovir via its own TK, a TK-deficient HSV strain will be cross-resistant to ganciclovir for the same reason. (The Wrong-Virus Distractor)
- D: Oseltamivir is a neuraminidase inhibitor with activity only against influenza A and B; it has no effect on herpesviruses. (The Mechanism-Substitution Trap)
This compound most likely shares its mechanism of action with which of the following drugs?
- A Tenofovir
- B Efavirenz
- C Bictegravir ✓ Correct
- D Darunavir
Why C is correct: Inhibition of proviral DNA integration into the host genome defines the integrase strand transfer inhibitor (INSTI) class, identifiable by the -tegravir suffix. Bictegravir is an INSTI and shares this mechanism. Reverse transcription and protein cleavage are explicitly preserved in the stem, ruling out drugs that act at those steps.
Why each wrong choice fails:
- A: Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI); it acts as a chain terminator during reverse transcription, a step the stem says is unaffected. (The Drug-Suffix Decoder)
- B: Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that allosterically inhibits reverse transcriptase, again at a step the stem rules out. (The Drug-Suffix Decoder)
- D: Darunavir is a protease inhibitor (-navir suffix) that blocks Gag-Pol polyprotein cleavage, but the stem states viral protein cleavage is preserved. (The Drug-Suffix Decoder)
Which combination most appropriately targets the HCV NS3/4A protease and the NS5A replication complex?
- A Sofosbuvir and ribavirin
- B Glecaprevir and pibrentasvir ✓ Correct
- C Tenofovir and entecavir
- D Ledipasvir and sofosbuvir
Why B is correct: Glecaprevir is an HCV NS3/4A protease inhibitor (-previr suffix), and pibrentasvir is an NS5A inhibitor (-asvir suffix); together they hit exactly the two targets named in the stem and form a pangenotypic 8-week regimen for treatment-naive non-cirrhotic patients. Recognizing suffix-to-mechanism mapping is the fastest path to the answer.
Why each wrong choice fails:
- A: Sofosbuvir is an NS5B polymerase inhibitor (-buvir), not a protease inhibitor, and ribavirin is a guanosine analog adjunct; this combination does not target NS3/4A or NS5A as the stem requires. (The Drug-Suffix Decoder)
- C: Tenofovir and entecavir are HBV nucleos(t)ide analogs that suppress HBV reverse transcription; they have no role in HCV therapy. (The Wrong-Virus Distractor)
- D: Ledipasvir is an NS5A inhibitor (-asvir) and sofosbuvir is an NS5B polymerase inhibitor (-buvir); this regimen covers NS5A and NS5B but not the NS3/4A protease specified in the stem. (The Drug-Suffix Decoder)
Memory aid
Drug-suffix decoder for HIV/HCV: -vir = antiviral, -navir = protease inhibitor, -tegravir = integrase inhibitor, -previr = HCV protease, -asvir = HCV NS5A, -buvir = HCV NS5B polymerase. For HSV, remember 'TK turns on acyclovir' — no TK, no activation, no effect.
Key distinction
Acyclovir requires viral thymidine kinase for the first phosphorylation; foscarnet and cidofovir do not. That is why TK-deficient HSV mutants are the classic acyclovir-resistant strain treated with foscarnet, and why ganciclovir resistance from UL97 mutations is also rescued by foscarnet.
Summary
Match the antiviral to the viral life-cycle step it blocks, and resistance almost always points to a mutation in that exact target — recognize the pattern and the answer follows.
Practice viruses and antivirals adaptively
Reading the rule is the start. Working USMLE Step 1 & 2-format questions on this sub-topic with adaptive selection, watching your mastery score climb in real time, and seeing the items you missed return on a spaced-repetition schedule — that's where score lift actually happens. Free for seven days. No credit card required.
Start your free 7-day trialFrequently asked questions
What is viruses and antivirals on the USMLE Step 1 & 2?
Antiviral drugs target distinct steps in the viral life cycle: attachment/entry, uncoating, genome replication (DNA polymerase, reverse transcriptase, RNA polymerase), integration, protein processing (protease), and release (neuraminidase). To pick the right drug or predict a resistance mechanism on the exam, first identify the virus family and its replication strategy, then match the drug class to the step it blocks. Resistance almost always traces back to a mutation in the viral target (thymidine kinase, reverse transcriptase, neuraminidase, NS5A) or to a missing activating enzyme.
How do I practice viruses and antivirals questions?
The fastest way to improve on viruses and antivirals is targeted, adaptive practice — working questions that focus on your specific weak spots within this sub-topic, getting immediate feedback, and revisiting items you missed on a spaced-repetition schedule. Neureto's adaptive engine does this automatically across the USMLE Step 1 & 2; start a free 7-day trial to see your sub-topic mastery climb in real time.
What's the most important distinction to remember for viruses and antivirals?
Acyclovir requires viral thymidine kinase for the first phosphorylation; foscarnet and cidofovir do not. That is why TK-deficient HSV mutants are the classic acyclovir-resistant strain treated with foscarnet, and why ganciclovir resistance from UL97 mutations is also rescued by foscarnet.
Is there a memory aid for viruses and antivirals questions?
Drug-suffix decoder for HIV/HCV: -vir = antiviral, -navir = protease inhibitor, -tegravir = integrase inhibitor, -previr = HCV protease, -asvir = HCV NS5A, -buvir = HCV NS5B polymerase. For HSV, remember 'TK turns on acyclovir' — no TK, no activation, no effect.
What's a common trap on viruses and antivirals questions?
Confusing acyclovir (HSV/VZV) with ganciclovir (CMV)
What's a common trap on viruses and antivirals questions?
Forgetting that foscarnet and cidofovir bypass viral kinases
Ready to drill these patterns?
Take a free USMLE Step 1 & 2 assessment — about 25 minutes and Neureto will route more viruses and antivirals questions your way until your sub-topic mastery score reflects real improvement, not luck. Free for seven days. No credit card required.
Start your free 7-day trial